

Focus on Faculty #27

Nathaniel Bouganim



[Dr. Nathaniel Bouganim](#) is an Assistant Professor in the Gerald Bronfman Department of Oncology. He completed his training in internal medicine and oncology at McGill University and his sub-specialty training in breast cancer, focusing on bone metastases and “patient centered care” with Dr. Mark Clemons at the Ottawa Integrative Cancer Centre and the National Cancer Institute of Canada (NCIC). He joined the McGill University Health Centre (MUHC) in 2011 as a medical oncologist specializing in breast cancer and head and neck cancers. He currently serves as the Director of the Oncology in-patient teaching unit at the MUHC.

Dr. Bouganim is not scared of challenges. In 2012 when Hôpital du Suroit in Salaberry-de-Valleyfield had no medical oncologists, Dr. Bouganim provided medical oncology expertise and assisted in the rebuilding of the department by helping with the hiring of oncologists.

Dr. Bouganim is a very active researcher with multiple investigator led clinical trials, and is principal investigator on numerous phase 1, 2 and 3 clinical trials in both breast and head and neck cancers. He is a member of the scientific committee for the McPeak Sirois group for clinical research in breast cancer as well as a member of the Comité d'évolution des pratiques en oncologie (CEPO) guideline committee. In addition, he has served as a breast cancer expert for Quebec's Institut national d'excellence en santé et en services sociaux (INESS).

During his spare time when he is not working at the hospital or at home with his four children, Dr. Bouganim pursues his passion as an avid cyclist and gets thrills in participating in Gran Fondos (mass participation cycling events) supporting a variety of causes including cancer.

We asked Dr. Bouganim to list a few of his articles whose work he is particularly proud or enjoyed the most. This is what he provided:

Clemons M, **Bouganim N**, Smith S, Mazzarello S, Vandermeer L, Segal R, Dent S, Gertler S, Song X, Wheatley-Price P, Dranitsaris G. Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial. *JAMA*. 2016 Feb;2(2):225-31

Azoulay L, Soldera S, Yin H, **Bouganim N**. Use of Calcium Channel Blockers and Risk of Breast Cancer: A Population-based Cohort Study. *Epidemiology*. 2016 Jul;27(4):594-601

Bouganim N, Tsvetkova E, Clemons M, Amir E. Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. *Breast Cancer Res Treat*. 2013 Jun;139(2):603